Histone deacetylase inhibitor treatment increases the expression of the plasma membrane Ca2+ pump PMCA4b and inhibits the migration of melanoma cells independent of ERK

Luca Hegedüs, Rita Padányi, Judit Molnár, K. Pászty, Karolina Varga, I. Kenessey, Eszter Sárközy, Matthias Wolf, Michael Grusch, Zoltán Hegyi, L. Homolya, Clemens Aigner, Tamás Garay, B. Hegedűs, J. Tímár, Enikö Kállay, A. Enyedi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Several new therapeutic options emerged recently to treat metastatic melanoma; however, the high frequency of intrinsic and acquired resistance among patients shows a need for new therapeutic options. Previously, we identified the plasma membrane Ca2+ ATPase 4b (PMCA4b) as a metastasis suppressor in BRAF-mutant melanomas and found that mutant BRAF inhibition increased the expression of the pump, which then inhibited the migratory and metastatic capability of the cells. Earlier it was also demonstrated that histone deacetylase inhibitors (HDACis) upregulated PMCA4b expression in gastric, colon, and breast cancer cells. In this study, we treated one BRAF wild-type and two BRAF-mutant melanoma cell lines with the HDACis, SAHA and valproic acid, either alone, or in combination with the BRAF inhibitor, vemurafenib. We found that HDACi treatment strongly increased the expression of PMCA4b in all cell lines irrespective of their BRAF mutational status, and this effect was independent of ERK activity. Furthermore, HDAC inhibition also enhanced the abundance of the housekeeping isoform PMCA1. Combination of HDACis with vemurafenib, however, did not have any additive effects on either PMCA isoform. We demonstrated that the HDACi-induced increase in PMCA abundance was coupled to an enhanced [Ca2+]i clearance rate and also strongly inhibited both the random and directional movements of A375 cells. The primary role of PMCA4b in these characteristic changes was demonstrated by treatment with the PMCA4-specific inhibitor, caloxin 1c2, which was able to restore the slower Ca2+ clearance rate and higher motility of the cells. While HDAC treatment inhibited cell motility, it decreased only modestly the ratio of proliferative cells and cell viability. Our results show that in melanoma cells the expression of both PMCA4b and PMCA1 is under epigenetic control and the elevation of PMCA4b expression either by HDACi treatment or by the decreased activation of the BRAF-MEK-ERK pathway can inhibit the migratory capacity of the highly motile A375 cells.

Original languageEnglish
Article number95
JournalFrontiers in Oncology
Volume7
Issue numberMAY
DOIs
Publication statusPublished - May 24 2017

Fingerprint

Histone Deacetylase Inhibitors
Calcium-Transporting ATPases
Cell Movement
Melanoma
Cell Membrane
Protein Isoforms
Therapeutics
Cell Line
Housekeeping
MAP Kinase Signaling System
Valproic Acid
Epigenomics
Colonic Neoplasms
Stomach Neoplasms
Cell Survival
Breast Neoplasms
Neoplasm Metastasis

Keywords

  • BRAF-mutant melanoma
  • Cell motility
  • HDAC inhibitors
  • PMCA1
  • PMCA4

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Histone deacetylase inhibitor treatment increases the expression of the plasma membrane Ca2+ pump PMCA4b and inhibits the migration of melanoma cells independent of ERK. / Hegedüs, Luca; Padányi, Rita; Molnár, Judit; Pászty, K.; Varga, Karolina; Kenessey, I.; Sárközy, Eszter; Wolf, Matthias; Grusch, Michael; Hegyi, Zoltán; Homolya, L.; Aigner, Clemens; Garay, Tamás; Hegedűs, B.; Tímár, J.; Kállay, Enikö; Enyedi, A.

In: Frontiers in Oncology, Vol. 7, No. MAY, 95, 24.05.2017.

Research output: Contribution to journalArticle

Hegedüs, Luca ; Padányi, Rita ; Molnár, Judit ; Pászty, K. ; Varga, Karolina ; Kenessey, I. ; Sárközy, Eszter ; Wolf, Matthias ; Grusch, Michael ; Hegyi, Zoltán ; Homolya, L. ; Aigner, Clemens ; Garay, Tamás ; Hegedűs, B. ; Tímár, J. ; Kállay, Enikö ; Enyedi, A. / Histone deacetylase inhibitor treatment increases the expression of the plasma membrane Ca2+ pump PMCA4b and inhibits the migration of melanoma cells independent of ERK. In: Frontiers in Oncology. 2017 ; Vol. 7, No. MAY.
@article{d7e574914a1b481987193565845eb262,
title = "Histone deacetylase inhibitor treatment increases the expression of the plasma membrane Ca2+ pump PMCA4b and inhibits the migration of melanoma cells independent of ERK",
abstract = "Several new therapeutic options emerged recently to treat metastatic melanoma; however, the high frequency of intrinsic and acquired resistance among patients shows a need for new therapeutic options. Previously, we identified the plasma membrane Ca2+ ATPase 4b (PMCA4b) as a metastasis suppressor in BRAF-mutant melanomas and found that mutant BRAF inhibition increased the expression of the pump, which then inhibited the migratory and metastatic capability of the cells. Earlier it was also demonstrated that histone deacetylase inhibitors (HDACis) upregulated PMCA4b expression in gastric, colon, and breast cancer cells. In this study, we treated one BRAF wild-type and two BRAF-mutant melanoma cell lines with the HDACis, SAHA and valproic acid, either alone, or in combination with the BRAF inhibitor, vemurafenib. We found that HDACi treatment strongly increased the expression of PMCA4b in all cell lines irrespective of their BRAF mutational status, and this effect was independent of ERK activity. Furthermore, HDAC inhibition also enhanced the abundance of the housekeeping isoform PMCA1. Combination of HDACis with vemurafenib, however, did not have any additive effects on either PMCA isoform. We demonstrated that the HDACi-induced increase in PMCA abundance was coupled to an enhanced [Ca2+]i clearance rate and also strongly inhibited both the random and directional movements of A375 cells. The primary role of PMCA4b in these characteristic changes was demonstrated by treatment with the PMCA4-specific inhibitor, caloxin 1c2, which was able to restore the slower Ca2+ clearance rate and higher motility of the cells. While HDAC treatment inhibited cell motility, it decreased only modestly the ratio of proliferative cells and cell viability. Our results show that in melanoma cells the expression of both PMCA4b and PMCA1 is under epigenetic control and the elevation of PMCA4b expression either by HDACi treatment or by the decreased activation of the BRAF-MEK-ERK pathway can inhibit the migratory capacity of the highly motile A375 cells.",
keywords = "BRAF-mutant melanoma, Cell motility, HDAC inhibitors, PMCA1, PMCA4",
author = "Luca Heged{\"u}s and Rita Pad{\'a}nyi and Judit Moln{\'a}r and K. P{\'a}szty and Karolina Varga and I. Kenessey and Eszter S{\'a}rk{\"o}zy and Matthias Wolf and Michael Grusch and Zolt{\'a}n Hegyi and L. Homolya and Clemens Aigner and Tam{\'a}s Garay and B. Hegedűs and J. T{\'i}m{\'a}r and Enik{\"o} K{\'a}llay and A. Enyedi",
year = "2017",
month = "5",
day = "24",
doi = "10.3389/fonc.2017.00095",
language = "English",
volume = "7",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "MAY",

}

TY - JOUR

T1 - Histone deacetylase inhibitor treatment increases the expression of the plasma membrane Ca2+ pump PMCA4b and inhibits the migration of melanoma cells independent of ERK

AU - Hegedüs, Luca

AU - Padányi, Rita

AU - Molnár, Judit

AU - Pászty, K.

AU - Varga, Karolina

AU - Kenessey, I.

AU - Sárközy, Eszter

AU - Wolf, Matthias

AU - Grusch, Michael

AU - Hegyi, Zoltán

AU - Homolya, L.

AU - Aigner, Clemens

AU - Garay, Tamás

AU - Hegedűs, B.

AU - Tímár, J.

AU - Kállay, Enikö

AU - Enyedi, A.

PY - 2017/5/24

Y1 - 2017/5/24

N2 - Several new therapeutic options emerged recently to treat metastatic melanoma; however, the high frequency of intrinsic and acquired resistance among patients shows a need for new therapeutic options. Previously, we identified the plasma membrane Ca2+ ATPase 4b (PMCA4b) as a metastasis suppressor in BRAF-mutant melanomas and found that mutant BRAF inhibition increased the expression of the pump, which then inhibited the migratory and metastatic capability of the cells. Earlier it was also demonstrated that histone deacetylase inhibitors (HDACis) upregulated PMCA4b expression in gastric, colon, and breast cancer cells. In this study, we treated one BRAF wild-type and two BRAF-mutant melanoma cell lines with the HDACis, SAHA and valproic acid, either alone, or in combination with the BRAF inhibitor, vemurafenib. We found that HDACi treatment strongly increased the expression of PMCA4b in all cell lines irrespective of their BRAF mutational status, and this effect was independent of ERK activity. Furthermore, HDAC inhibition also enhanced the abundance of the housekeeping isoform PMCA1. Combination of HDACis with vemurafenib, however, did not have any additive effects on either PMCA isoform. We demonstrated that the HDACi-induced increase in PMCA abundance was coupled to an enhanced [Ca2+]i clearance rate and also strongly inhibited both the random and directional movements of A375 cells. The primary role of PMCA4b in these characteristic changes was demonstrated by treatment with the PMCA4-specific inhibitor, caloxin 1c2, which was able to restore the slower Ca2+ clearance rate and higher motility of the cells. While HDAC treatment inhibited cell motility, it decreased only modestly the ratio of proliferative cells and cell viability. Our results show that in melanoma cells the expression of both PMCA4b and PMCA1 is under epigenetic control and the elevation of PMCA4b expression either by HDACi treatment or by the decreased activation of the BRAF-MEK-ERK pathway can inhibit the migratory capacity of the highly motile A375 cells.

AB - Several new therapeutic options emerged recently to treat metastatic melanoma; however, the high frequency of intrinsic and acquired resistance among patients shows a need for new therapeutic options. Previously, we identified the plasma membrane Ca2+ ATPase 4b (PMCA4b) as a metastasis suppressor in BRAF-mutant melanomas and found that mutant BRAF inhibition increased the expression of the pump, which then inhibited the migratory and metastatic capability of the cells. Earlier it was also demonstrated that histone deacetylase inhibitors (HDACis) upregulated PMCA4b expression in gastric, colon, and breast cancer cells. In this study, we treated one BRAF wild-type and two BRAF-mutant melanoma cell lines with the HDACis, SAHA and valproic acid, either alone, or in combination with the BRAF inhibitor, vemurafenib. We found that HDACi treatment strongly increased the expression of PMCA4b in all cell lines irrespective of their BRAF mutational status, and this effect was independent of ERK activity. Furthermore, HDAC inhibition also enhanced the abundance of the housekeeping isoform PMCA1. Combination of HDACis with vemurafenib, however, did not have any additive effects on either PMCA isoform. We demonstrated that the HDACi-induced increase in PMCA abundance was coupled to an enhanced [Ca2+]i clearance rate and also strongly inhibited both the random and directional movements of A375 cells. The primary role of PMCA4b in these characteristic changes was demonstrated by treatment with the PMCA4-specific inhibitor, caloxin 1c2, which was able to restore the slower Ca2+ clearance rate and higher motility of the cells. While HDAC treatment inhibited cell motility, it decreased only modestly the ratio of proliferative cells and cell viability. Our results show that in melanoma cells the expression of both PMCA4b and PMCA1 is under epigenetic control and the elevation of PMCA4b expression either by HDACi treatment or by the decreased activation of the BRAF-MEK-ERK pathway can inhibit the migratory capacity of the highly motile A375 cells.

KW - BRAF-mutant melanoma

KW - Cell motility

KW - HDAC inhibitors

KW - PMCA1

KW - PMCA4

UR - http://www.scopus.com/inward/record.url?scp=85020073101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020073101&partnerID=8YFLogxK

U2 - 10.3389/fonc.2017.00095

DO - 10.3389/fonc.2017.00095

M3 - Article

AN - SCOPUS:85020073101

VL - 7

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - MAY

M1 - 95

ER -